- Trials with a EudraCT protocol (2,060)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
2,060 result(s) found.
Displaying page 32 of 103.
EudraCT Number: 2017-002491-10 | Sponsor Protocol Number: Alofisel-4001 | Start Date*: 2020-03-10 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula | |||||||||||||
Medical condition: Perianal fistulising Crohn´s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) ES (Ongoing) DE (Ongoing) FR (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003204-39 | Sponsor Protocol Number: BT–L-CsA–301–SLT | Start Date*: 2019-01-09 |
Sponsor Name:BREATH Therapeutics Inc. | ||
Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA... | ||
Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006057-21 | Sponsor Protocol Number: CABL001A2302 | Start Date*: 2021-09-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosi... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001565-33 | Sponsor Protocol Number: RA101495-02.302 | Start Date*: 2020-04-24 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004124-10 | Sponsor Protocol Number: 68284528MMY2003 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) BE (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005724-38 | Sponsor Protocol Number: TL-895-209 | Start Date*: 2022-05-18 | |||||||||||
Sponsor Name:Telios Pharma, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects a... | |||||||||||||
Medical condition: Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects with MF who have a Suboptimal Response to Ruxolitinib | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) IT (Ongoing) ES (Ongoing) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005932-50 | Sponsor Protocol Number: BCX7353-304 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:BioCryst Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE | |||||||||||||
Medical condition: Hereditary Angioedema (HAE) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) IT (Ongoing) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003374-91 | Sponsor Protocol Number: SRP-9001-301 | Start Date*: 2022-09-12 | ||||||||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBA... | ||||||||||||||||||
Medical condition: Duchenne Muscular Dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004786-25 | Sponsor Protocol Number: AC-077A301 | Start Date*: 2019-09-05 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of maciten... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) PL (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003441-38 | Sponsor Protocol Number: 1042-TSC-3001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Marinus Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC)-related epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) ES (Ongoing) IT (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003809-60 | Sponsor Protocol Number: XPORT-MF-035 | Start Date*: 2021-07-27 | |||||||||||||||||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
Full Title: A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis | |||||||||||||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Ongoing) PL (Temporarily Halted) GR (Ongoing) IT (Ongoing) ES (Temporarily Halted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003467-26 | Sponsor Protocol Number: NN7769-4516 | Start Date*: 2021-11-30 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with haemophilia A with or without FVIII inhibitors | ||||||||||||||||||
Medical condition: Haemophilia A Haemophilia A with inhibitors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) PL (Ongoing) IT (Ongoing) ES (Ongoing) PT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004313-39 | Sponsor Protocol Number: TCH-306EXT | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) SK (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006709-31 | Sponsor Protocol Number: COAV101B12302 | Start Date*: 2022-11-03 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 yea... | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001829-40 | Sponsor Protocol Number: 201 | Start Date*: 2019-01-02 | |||||||||||
Sponsor Name:Y-mAbs Therapeutics A/S | |||||||||||||
Full Title: A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete... | |||||||||||||
Medical condition: Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001831-17 | Sponsor Protocol Number: MT-7117-A-301 | Start Date*: 2022-04-07 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Development America (MTDA), Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Pr... | |||||||||||||
Medical condition: Erythropoietic Protoporphyria or X-Linked Protoporphyria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) ES (Ongoing) SE (Ongoing) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000665-32 | Sponsor Protocol Number: 80202135SJS2001 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing) PT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003855-40 | Sponsor Protocol Number: MOR208C115 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref... | |||||||||||||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) CZ (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date*: 2023-08-10 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004998-32 | Sponsor Protocol Number: ARGX-117-2003 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Mult... | |||||||||||||
Medical condition: Multifocal Motor Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
